Insulin Glargine: Mechanism, Formulations, and Safety

Insulin glargine is a long-acting insulin analog engineered to provide a slow, steady release of insulin over roughly 24 hours, mimicking the low-level background insulin that a healthy pancreas secretes between meals and overnight. First approved in 2000 under the brand name Lantus, it became one of the most widely prescribed basal insulins in the world for both type 1 and type 2 diabetes. Its defining feature is a flat, peakless activity profile that distinguishes it from older basal insulins and translates into fewer episodes of low blood sugar, particularly at night.

How the Molecule Was Redesigned

Insulin glargine starts with the same basic structure as human insulin but carries two small modifications. Two extra arginine amino acids are added to the end of one chain (the B-chain), and a single amino acid swap is made on the other chain (glycine replaces asparagine at one position). These tweaks shift the molecule’s isoelectric point, which is the pH at which the protein has no net electrical charge and is least soluble in water. Native human insulin has an isoelectric point around 5.4; glargine’s sits at about 6.7, much closer to the body’s neutral pH of roughly 7.4.¹ The practical consequence: glargine is formulated in an acidic solution (pH about 4) that keeps it dissolved in the vial or pen cartridge. Once injected into the neutral pH of subcutaneous tissue, the molecules lose their solubility and clump together into a tiny solid deposit, or microprecipitate.

The Depot Effect and Slow Absorption

That microprecipitate under the skin acts as a drug depot. Instead of flooding the bloodstream all at once, insulin glargine dissolves gradually from the surface of the precipitate and trickles into surrounding capillaries over many hours. Mathematical models of this process show that the rate of redissolution depends on the surface area of the depot, meaning the release naturally tapers as the deposit shrinks.² This surface-area-driven release is what gives glargine its remarkably even action profile.

Once glargine molecules leave the depot and enter the bloodstream, enzymes quickly clip off the extra arginine residues on the B-chain. The main circulating form is known as metabolite 1 (M1), which is structurally very close to native human insulin. A second metabolite, M2, also appears. Both M1 and M2 are found at the injection site and in plasma, meaning the conversion begins locally before the drug even reaches the general circulation.³⁴ In practice, it is M1 that does most of the blood-sugar-lowering work in your body, not the intact glargine molecule.

The Peakless Profile

Older basal insulins like NPH and ultralente both produce a noticeable peak in blood insulin levels several hours after injection, followed by a gradual decline. Glargine behaves differently. In head-to-head clamp studies, NPH peaked at about four and a half hours and wore off around 14 hours, while ultralente peaked near 10 hours with an endpoint around 20 hours. Glargine showed no peak at all and maintained a flat concentration and action profile lasting roughly 22 hours, closely resembling the steady delivery of a continuous subcutaneous insulin pump.⁵

The onset of action is a bit slower, too, at about an hour and a half versus under an hour for NPH. But the tradeoff is meaningful: the variability in insulin levels between different people using glargine was significantly lower than with either NPH or ultralente, and comparable to that of an insulin pump. Less person-to-person variability means more predictable blood sugar control, which is one reason glargine quickly became a preferred basal insulin worldwide.

Fewer Lows, Especially at Night

The flat profile pays off clinically in the form of reduced hypoglycemia. A meta-analysis comparing glargine to NPH in people with type 2 diabetes found that glargine reduced overall symptomatic hypoglycemia by about 11% and nocturnal hypoglycemia by about 26%. The reductions were even more striking for severe episodes: severe hypoglycemia dropped by roughly 46%, and severe nocturnal hypoglycemia by about 59%.⁶ Individual trials consistently echoed this pattern. In one study using bedtime dosing, only about 10% of people on glargine experienced nocturnal lows, compared with 24% of those on NPH.⁷

For many people, the nighttime advantage alone justifies choosing glargine. Nocturnal hypoglycemia is dangerous because you may not wake up to treat it, and the fear of overnight lows is one of the biggest barriers to people accepting insulin therapy in the first place. A basal insulin that substantially reduces that risk removes a real psychological and physical obstacle.

Standard Versus Concentrated Formulations

Insulin glargine is available in two concentrations. The original, marketed as Lantus, contains 100 units per milliliter (U-100, sometimes called Gla-100). A more concentrated version, Toujeo, delivers 300 units per milliliter (Gla-300). The higher concentration means a smaller injected volume, which creates a more compact depot under the skin and further slows the absorption. In practice, Gla-300 produces an even flatter and longer-lasting profile than Gla-100.

The EDITION series of clinical trials, involving about 3,500 people with type 1 and type 2 diabetes across six pivotal studies, compared the two formulations head to head.⁸ In type 1 diabetes specifically, HbA1c reductions were essentially identical over 12 months between Gla-300 and Gla-100, and hypoglycemia rates did not differ significantly regardless of time of day or blood sugar threshold used to define an episode. One wrinkle: people on Gla-300 needed about 20% more units per day to achieve the same glucose control, because the slower absorption means slightly more insulin stays tied up in the depot at any given moment.⁹ The extra units do not translate to extra cost per se, since Toujeo pens are designed to account for the higher concentration, but it is something prescribers and patients should be aware of when adjusting doses.

Does Injection Timing Matter?

One of the practical questions people on glargine often ask is whether it matters if they inject in the morning or at bedtime. The short answer is that both work. A study of Gla-300 found that morning and evening injections produced comparable reductions in fasting blood glucose, post-meal glucose, and HbA1c over three months. Nocturnal hypoglycemia was numerically lower with morning dosing, and overall hypoglycemia numerically lower with evening dosing, but neither difference was statistically significant.¹⁰

A small pilot study in people with type 1 diabetes who were not well controlled on bedtime Gla-100 found that switching to morning injection actually improved HbA1c and reduced both morning and nocturnal lows.¹¹ The take-home message is that consistency matters more than the clock. Pick the time that fits your routine and stick with it. If you are having unexplained lows or running high at a particular time of day, your doctor may suggest shifting the injection window, but there is no universal “best” time.

Cardiovascular and Cancer Safety

When insulin glargine was first introduced, some researchers raised theoretical concerns that its slightly higher affinity for the IGF-1 receptor could promote cardiovascular problems or cancer growth. The ORIGIN trial was designed to settle these questions once and for all. It enrolled over 12,000 people with early type 2 diabetes or prediabetes and followed them for more than six years.

The results were reassuring. Cardiovascular event rates were virtually identical between people randomized to glargine and those receiving standard care, with no increase in heart attacks, strokes, or cardiovascular deaths.¹² There was also no difference in cancer incidence. The only notable side effects were a modest weight gain of about 1.6 kilograms in the glargine group and higher rates of severe hypoglycemia, roughly three times the rate in the standard-care arm, though the absolute rate was still low at about one event per 100 person-years.

Extended follow-up after the trial ended continued to show no difference in heart attacks, strokes, cardiovascular death, or cancer between the glargine and standard-care groups.¹³ Separate analyses confirmed that glargine’s cardiovascular neutrality held true even in participants with higher levels of insulin resistance.¹⁴ Animal studies have shown that glargine can upregulate certain growth-factor receptors in tissues like the liver and colon, which keeps the theoretical debate alive in laboratory settings.¹⁵ But at the doses and durations people actually use, the large-scale human data is clear: glargine does not raise your risk of cardiovascular disease or cancer.

How Glargine Compares to Insulin Degludec

Insulin degludec (brand name Tresiba) is the other major ultra-long-acting basal insulin on the market. Its mechanism differs from glargine’s: degludec forms multi-hexamer chains after injection that slowly dissociate, rather than precipitating into a microprecipitate. In a randomized crossover study in people with type 1 diabetes, degludec produced slightly lower fasting blood glucose levels and slightly less day-to-day variability in fasting glucose than glargine U-100, at a slightly smaller daily dose.¹⁶ Degludec also has a longer duration of action (beyond 42 hours) and can be dosed at flexible times without significant glucose fluctuation.

In practice, the choice between the two often comes down to insurance coverage, pen device preference, and individual response. Both are effective peakless basal insulins with favorable hypoglycemia profiles relative to NPH. Gla-300 narrows the gap between glargine and degludec on variability, since its more compact depot also produces a flatter profile than original Gla-100.

Use in Pregnancy

NPH has traditionally been the basal insulin of choice during pregnancy because it has the longest track record, but glargine has been accumulating safety data of its own. Placental perfusion studies found that at the concentrations seen during normal therapeutic dosing, insulin glargine did not cross the placenta to any detectable degree. Even at concentrations a thousand-fold higher than therapeutic levels, only trivial amounts transferred to the fetal side.¹⁷

A systematic review and meta-analysis comparing glargine to NPH in pregnant women found no statistically significant differences in fetal outcomes between the two.¹⁸ Many endocrinologists now feel comfortable continuing glargine in a woman who was already using it before becoming pregnant, rather than switching to NPH and introducing a new insulin regimen during an already challenging period. That said, guidelines vary by country and institution, and the conversation should happen with your care team early in pregnancy.

Children, Older Adults, and Kidney Disease

Glargine is used across the age spectrum. In a study of children and adolescents with type 1 diabetes, including toddlers, six months of glargine therapy lowered average HbA1c from about 7.6% to 7.1%. Among the youngest children (preschool age), the drop was even steeper, from about 7.5% to 7.0%. Severe hypoglycemic episodes fell roughly 40% compared with the six months before starting glargine.¹⁹ The pen devices and predictable profile make it particularly useful for families trying to manage a small child’s blood sugar.

At the other end of the spectrum, older adults and people with kidney disease require extra caution. As kidney function declines, insulin clearance slows, effectively making each dose last longer and hit harder. In a retrospective study of people with type 2 diabetes and advanced chronic kidney disease using glargine, about a third experienced documented hypoglycemia, and roughly a quarter had nocturnal lows.²⁰ Glargine is still used in these patients, but doses typically need to be reduced and blood sugar checked more frequently.

Biosimilars and Interchangeability

As the original Lantus patents have expired, several biosimilar versions of insulin glargine have come to market. These are not generic drugs in the traditional sense, because biologics made from living cells cannot be copied identically the way a small-molecule pill can. Instead, biosimilars must demonstrate through rigorous analytical, pharmacokinetic, and clinical testing that they are highly similar to the reference product with no meaningful differences in safety or effectiveness.²¹

One glargine biosimilar, insulin glargine-yfgn (brand name Semglee), went a step further and earned an “interchangeable” designation from the FDA. The INSTRIDE trials showed it was noninferior to reference glargine in blood sugar reduction and side effects, and a switching study demonstrated that patients could be moved back and forth between the biosimilar and the reference product without any change in glucose control or adverse events.²² The interchangeable label means a pharmacist can substitute it for Lantus without calling the prescriber, in accordance with state laws. For patients, this can translate into significant savings at the pharmacy counter.

Antibody Responses

Because insulin glargine is a modified protein, it can trigger the immune system to produce anti-insulin antibodies. This happens with all injected insulins to some degree, but the question is whether those antibodies cause any real trouble. Multiple studies comparing different glargine products found that while some patients did develop detectable antibodies, the levels were generally low (under 5%), and there was no association between antibody levels and clinical outcomes like blood sugar control, insulin dose requirements, or hypoglycemia rates.²³²⁴ Even among patients with the highest antibody levels (upper quartile), clinical outcomes were no different. For the vast majority of people, antibody formation is a laboratory finding without any practical significance.

The Economics of Basal Insulin Choice

Insulin costs remain a charged topic, and glargine has been part of that conversation since its launch. Economic modeling studies that compared glargine to NPH in type 2 diabetes generally found glargine to be cost-effective over a long time horizon, projecting gains in both life expectancy and quality-adjusted life years driven largely by fewer hypoglycemic episodes and better overnight glucose control.²⁵ In type 1 diabetes, one German analysis projected that glargine would save money compared with NPH over 40 years while also improving quality-adjusted life years, making it the dominant strategy in that model.²⁶

These analyses do depend on modeling assumptions and are country-specific, so their conclusions do not transfer automatically everywhere. Still, the arrival of biosimilar and interchangeable glargine products has reshaped the cost landscape considerably. In markets where biosimilars have gained traction, out-of-pocket costs for a month of basal insulin have dropped. For many people, the combination of a well-studied efficacy and safety record with increasingly affordable pricing makes glargine a practical first choice when starting basal insulin therapy.